复星医药(02196.HK)：控股子公司Gland Pharma拟在印度证交所和孟买证交所上市
格隆汇11月1日丨复星医药(02196.HK)宣布，于2019年11月1日举行的会议上已审议并批准建议分拆Gland Pharma并于印度证交所和孟买证交所境外上市的议案。
Gland Pharma于1978年在印度注册成立。截至公告日期，公司附属公司Fosun Pharma Industrial Pte. Ltd.、Lustrous Star Limited、Regal Gesture Limited、Ample Up Limited以及复星实业(香港)有限公司持有Gland Pharma合共计约74%的股份。因此，公司间接持有Gland Pharma合共计约74%的股份。Gland Pharma主要从事小分子注射剂仿制药的开发及生产。
根据上市议案，发行方式包括Gland Pharma境外上市采取公开发行新股和/或现有股东公开发售股份(即存量股转让，下同)的方式进行，Gland Pharma境外上市的股份将在印度证交所和孟买证交所公开发售。其中，新增股份规模拟定为不超过Gland Pharma境外上市前其总股本的5%、现有股东公开发售股份规模拟定为不超过Gland Pharma境外上市前其总股本的22.5%。公司拟定转让的存量股份数量不超过Gland Pharma境外上市前其总股本的12.5%。
据悉，Gland Pharma的境外上市不会对集团各业务板块的持续运营运作构成任何实质性影响。一方面，通过Gland Pharma境外上市，有利于Gland Pharma在其本土市场进一步发展壮大，优化其公司治理及资本结构，继续扩大其行业领先优势，并有利于提升公司作为控股股东的声誉和投资回报；另一方面，如果Gland Pharma境外上市成功获得独立融资平台，也有助于集团各业务板块通过公司直接融资更好地获得发展。因此，Gland Pharma境外上市将会有力促进公司控股战略的升级，将会进一步巩固集团的核心竞争力，并促进集团的可持续发展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
